Loading
institutionsInstitution
Hospital Universitario 12 de Octubre
One of Madrid's largest hospitals, a leading site for lung cancer and myeloma trials and for academic CAR-T development.
Also called: H12Oi+12 Research Institute
Overview
The Hospital Universitario 12 de Octubre and its research institute i+12 host the H12O-CNIO Lung Cancer Clinical Research Unit led by Luis Paz-Ares, one of the most active investigators in small-cell and non-small-cell lung cancer trials including the tarlatamab programme, and a haematology department under Joaquín Martínez-López that pioneered next-generation sequencing for minimal residual disease in myeloma and co-developed the academic BCMA CAR-T ARI-0002h with Hospital Clínic. The hospital is a major transplant centre, runs paediatric oncology and neuro-oncology services and a phase 1 unit. Its proximity to the CNIO underpins joint translational programmes.
Location
Madrid, ES
Type
hospital · Universidad Complutense de Madrid
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#85 · 42 points (0 Newsweek + 0 NCI + 42 from 21 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Hospital Universitario 12 De Octubre, including child institutions. 765 works · 13,961 citations · 74% open access · 21% clinical trials · 1% reviews.
Oncology works per year
1412022
1642023
1752024
1702025
1152026
Most works
- Luis Paz-Ares115 works
- Rocio García‐Carbonero36 works
- Joaquín Martínez‐López33 works
- Enriqueta Felip33 works
- Ana Jiménez Ubieto32 works
- Mariana Bastos‐Oreiro30 works
- Jon Zugazagoitia30 works
- Martin Reck29 works
- Eva Ciruelos29 works
- Josep M. Tabernero25 works
Most cited
- H12O-CNIO Lung Cancer Unit
- Myeloma and MRD by NGS
- Academic CAR-T
- Transplantation
- Phase 1 unit
Carmen Martínez de Pancorbo González
Representative of Hospital Universitario 12 de Octubre to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Carmen Martínez de Pancorbo González represents Hospital Universitario 12 de Octubre in the Organisation of European Cancer Institutes, which lists the centre among its members in Spain.
Joaquín Martínez-López
Head of the Haematology Department
Multiple myelomaHaematological malignanciesMinimal residual disease
Haematologist who heads the Haematology Department at Hospital 12 de Octubre and the joint H12O-CNIO haematological malignancies unit, known for myeloma and MRD research.
Luis Paz-Ares
Head of the H12O-CNIO Lung Cancer Clinical Research Unit
Lung cancerThoracic oncologyEarly-phase clinical trials
Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer.
Similar pages
- InstitutionHospital Universitario La Paz
Shares Hospital Universitario Puerta de Hierro Majadahonda, Hospital Clínico San Carlos, Hospital Universitario de La Princesa, Hospital Universitario Ramón y Cajal.
- InstitutionHospital General Universitario Gregorio Marañón
Shares Hospital Clínico San Carlos, Hospital Universitario de La Princesa, Hospital Universitario Ramón y Cajal.
- TrialDeLLphi-305
Shares DLL3, Tarlatamab, T-cell engagers (bispecific), Durvalumab.
- TrialDeLLphi-304
Shares Luis Paz-Ares, DLL3, Tarlatamab, T-cell engagers (bispecific).
- TrialA Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small
Shares Tarlatamab, T-cell engagers (bispecific), Durvalumab, Small-cell lung cancer.
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy.
- TrialTarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Shares Tarlatamab, T-cell engagers (bispecific), Durvalumab, Immune checkpoint inhibitors.
- TermSmall-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11
Shares DLL3, Tarlatamab, Durvalumab, Small-cell lung cancer.
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-PD-L1)
Durvalumab · Imfinzi
ApprovedBispecific T-cell engager (DLL3×CD3)
Tarlatamab · Imdelltra